Rationale for Ras and Raf-kinase as a Target for Cancer Therapeutics

E-ISSN： 1873-4286|8|25|2231-2242

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.8, Iss.25, 2002-11, pp. : 2231-2242

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

EphA2 Receptor Tyrosine Kinase as a Promising Target for Cancer Therapeutics

Current Cancer Drug Targets, Vol. 5, Iss. 3, 2005-05 ,pp. : 149-157

Bentham Science Publishers

Access to resources Recommend Favorite

New RAF kinase inhibitors in cancer therapy

By Martin-Liberal Juan Larkin James

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 9, 2014-06 ,pp. : 1235-1245

Informa Healthcare

Access to resources Recommend Favorite

Raf kinase inhibitory protein (RKIP): A physiological regulator and future therapeutic target

By Zeng Lingchun Imamoto Akira Rosner Marsha Rich

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 10, 2008-10 ,pp. : 1275-1287

Informa Healthcare

Access to resources Recommend Favorite

Phase I/II RAF kinase inhibitors in cancer therapy

By Turajlic Samra Ali Zohra Yousaf Nadia Larkin James

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 739-749

Informa Healthcare

Access to resources Recommend Favorite

Small Molecule Kinase Inhibitors as Anti-Cancer Therapeutics

Mini Reviews in Medicinal Chemistry, Vol. 12, Iss. 5, 2012-05 ,pp. : 399-411

Bentham Science Publishers

Access to resources Recommend Favorite